CARAGLIA, MICHELE
 Distribuzione geografica
Continente #
EU - Europa 429
NA - Nord America 383
AS - Asia 84
OC - Oceania 1
Totale 897
Nazione #
US - Stati Uniti d'America 382
GB - Regno Unito 209
IE - Irlanda 88
CN - Cina 48
UA - Ucraina 30
SE - Svezia 28
IT - Italia 27
VN - Vietnam 18
FR - Francia 14
DE - Germania 8
FI - Finlandia 8
TR - Turchia 8
IN - India 6
ES - Italia 5
RU - Federazione Russa 5
BE - Belgio 3
AT - Austria 2
SG - Singapore 2
AU - Australia 1
BD - Bangladesh 1
CA - Canada 1
IR - Iran 1
LT - Lituania 1
PL - Polonia 1
Totale 897
Città #
Southend 199
Dublin 85
Fairfield 56
Chandler 32
Ashburn 31
Menlo Park 31
Woodbridge 26
Jacksonville 24
Seattle 21
Wilmington 20
Cambridge 19
Dong Ket 18
Beijing 17
Siena 16
Ann Arbor 15
Dearborn 14
Houston 14
New York 12
Princeton 10
Izmir 8
Helsinki 7
Málaga 5
Nanjing 5
Boardman 4
Fremont 4
San Diego 4
San Mateo 4
Shanghai 4
Brussels 3
Florence 3
Hebei 3
Moscow 3
Munich 3
Phoenix 3
Shenyang 3
Fuzhou 2
Hounslow 2
Jinan 2
Nanchang 2
Sezze 2
Tianjin 2
Vienna 2
Bangalore 1
Borghetto Lodigiano 1
Campi Bisenzio 1
Canberra 1
Dhaka 1
Edinburgh 1
Falkenstein 1
Giussano 1
Hangzhou 1
Jiaxing 1
Kilburn 1
Kunming 1
Kyiv 1
London 1
Los Angeles 1
Philadelphia 1
Saint Louis 1
Saint Petersburg 1
Sandston 1
Singapore 1
Taizhou 1
Toronto 1
Warsaw 1
Zanjan 1
Totale 764
Nome #
Anti-cancer activity of dose-fractioned mPE +/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients 239
Systemic inflammatory status predict the outcome of k-RAS WT metastatic colorectal cancer patients receiving the thymidylate synthase poly-epitope-peptide anticancer vaccine 231
Immuno-Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab 175
Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev). 147
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients 101
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 25
Totale 918
Categoria #
all - tutte 2.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.506


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020187 27 4 9 17 14 23 24 20 14 21 7 7
2020/2021163 10 11 5 21 7 20 2 20 18 15 8 26
2021/202296 5 16 4 4 9 0 7 4 9 12 7 19
2022/2023110 5 12 18 15 11 17 4 7 6 7 5 3
2023/2024140 1 1 14 7 3 38 63 0 2 5 0 6
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 918